Lupin Spearheads Epilepsy Awareness Campaign, Empowering Patients in India

As of November 17, 2025, Lupin, a leading pharmaceutical company, is spearheading a comprehensive initiative to transform the treatment and perceptions of epilepsy in India. Epilepsy, a chronic neurological disorder affecting nearly 14 million individuals in the country, has long been entangled in misinformation and social stigma, despite medical advances that allow 70% of those living with the condition to lead normal, productive lives.

Recognizing the need for greater awareness, Lupin has collaborated with over 500 neurologists across India to address key questions and disseminate accurate information about epilepsy through the #livebeyondepilepsy campaign. The educational content, produced in vernacular languages, aims to reach a wider audience and dispel the persistent myths that often view epilepsy as a curse rather than a manageable medical condition.

Lupin's ongoing mission is to advance treatments that transform hope into healing, with a focus on the central nervous system. The company continues to invest in innovative solutions for the neurological community, including therapies for rare forms of epilepsy, as part of its commitment to supporting those affected by the disorder and empowering them to live fulfilling lives beyond their diagnosis.